Login to Your Account

Financings Roundup

Spinout Obseva Targets Preterm Labor Drug

By Marie Powers
Staff Writer

Wednesday, August 28, 2013
Merck Serono SA spinout Obseva SA hit the ground running with a CHF32 million (US$34.7 million) Series A financing led by Sofinnova Partners and co-led by Sofinnova Ventures and Novo A/S.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription